O	0	10	Comparison
O	11	13	of
B-intervention	14	25	fulvestrant
O	26	32	versus
B-control	33	42	tamoxifen
O	43	46	for
O	47	50	the
O	51	60	treatment
O	61	63	of
O	64	72	advanced
O	73	79	breast
O	80	86	cancer
O	87	89	in
O	90	104	postmenopausal
O	105	110	women
O	111	121	previously
O	122	131	untreated
O	132	136	with
O	137	146	endocrine
O	147	154	therapy
O	154	155	:
O	156	157	a
O	158	171	multinational
O	171	172	,
O	173	179	double
O	179	180	-
O	180	185	blind
O	185	186	,
O	187	197	randomized
O	198	203	trial
O	203	204	.

O	205	207	To
O	208	216	evaluate
O	217	220	the
O	221	229	efficacy
O	230	233	and
O	234	246	tolerability
O	247	249	of
O	250	261	fulvestrant
O	262	263	(
O	263	271	Faslodex
O	271	272	;
O	273	284	AstraZeneca
O	285	300	Pharmaceuticals
O	301	303	LP
O	303	304	,
O	305	315	Wilmington
O	315	316	,
O	317	319	DE
O	319	320	)
O	320	321	,
O	322	323	a
O	324	327	new
O	328	336	estrogen
O	337	345	receptor
O	346	347	(
O	347	349	ER
O	349	350	)
O	351	361	antagonist
O	362	366	that
O	367	380	downregulates
O	381	383	ER
O	384	387	and
O	388	391	has
O	392	394	no
O	395	402	agonist
O	403	410	effects
O	410	411	,
O	412	418	versus
O	419	428	tamoxifen
O	428	429	,
O	430	432	an
O	433	445	antiestrogen
O	446	450	with
O	451	458	agonist
O	459	462	and
O	463	473	antagonist
O	474	481	effects
O	481	482	,
O	483	486	for
O	487	490	the
O	491	500	treatment
O	501	503	of
O	504	512	advanced
O	513	519	breast
O	520	526	cancer
O	527	529	in
O	530	544	postmenopausal
O	545	550	women
O	550	551	.

O	552	554	In
O	555	559	this
O	560	571	multicenter
O	571	572	,
O	573	579	double
O	579	580	-
O	580	585	blind
O	585	586	,
O	587	597	randomized
O	598	603	trial
O	603	604	,
B-eligibility	605	613	patients
I-eligibility	614	618	with
I-eligibility	619	629	metastatic
I-eligibility	629	630	/
I-eligibility	630	637	locally
I-eligibility	638	646	advanced
I-eligibility	647	653	breast
I-eligibility	654	660	cancer
I-eligibility	661	671	previously
I-eligibility	672	681	untreated
I-eligibility	682	685	for
I-eligibility	686	694	advanced
I-eligibility	695	702	disease
O	703	707	were
O	708	716	randomly
O	717	725	assigned
O	726	728	to
O	729	736	receive
O	737	743	either
O	744	755	fulvestrant
O	756	757	(
O	757	760	250
O	761	763	mg
O	763	764	,
O	765	768	via
O	769	782	intramuscular
O	783	792	injection
O	792	793	,
O	794	798	once
O	799	806	monthly
O	806	807	;
O	808	809	n
O	810	811	=
B-intervention-participants	812	815	313
O	815	816	)
O	817	819	or
O	820	829	tamoxifen
O	830	831	(
O	831	833	20
O	834	836	mg
O	836	837	,
O	838	844	orally
O	844	845	,
O	846	850	once
O	851	856	daily
O	856	857	;
O	858	859	n
O	860	861	=
B-control-participants	862	865	274
O	865	866	)
O	866	867	.

O	868	876	Patients
O	876	877	'
O	878	884	tumors
O	885	889	were
O	890	898	positive
O	899	902	for
O	903	905	ER
O	906	907	(
O	907	909	ER
O	909	910	+
O	910	911	)
O	912	915	and
O	915	916	/
O	916	918	or
O	919	931	progesterone
O	932	940	receptor
O	941	942	(
O	942	945	PgR
O	945	946	+
O	946	947	)
O	947	948	,
O	949	951	or
O	952	955	had
O	956	958	an
O	959	966	unknown
O	967	975	receptor
O	976	982	status
O	982	983	.

O	984	986	At
O	987	988	a
O	989	995	median
O	996	1002	follow
O	1002	1003	-
O	1003	1005	up
O	1006	1008	of
O	1009	1011	14
O	1011	1012	.
O	1012	1013	5
O	1014	1020	months
O	1020	1021	,
O	1022	1027	there
O	1028	1031	was
O	1032	1034	no
O	1035	1046	significant
O	1047	1057	difference
O	1058	1065	between
O	1066	1077	fulvestrant
O	1078	1081	and
O	1082	1091	tamoxifen
O	1092	1095	for
O	1096	1099	the
O	1100	1107	primary
O	1108	1111	end
O	1112	1117	point
O	1118	1120	of
B-outcome	1121	1125	time
I-outcome	1126	1128	to
I-outcome	1129	1140	progression
O	1141	1142	(
O	1142	1145	TTP
O	1145	1146	;
O	1147	1153	median
O	1154	1157	TTP
O	1157	1158	,
B-iv-cont-median	1159	1160	6
I-iv-cont-median	1160	1161	.
I-iv-cont-median	1161	1162	8
I-iv-cont-median	1163	1169	months
O	1170	1173	and
B-cv-cont-median	1174	1175	8
I-cv-cont-median	1175	1176	.
I-cv-cont-median	1176	1177	3
I-cv-cont-median	1178	1184	months
O	1184	1185	,
O	1186	1198	respectively
O	1198	1199	;
O	1200	1206	hazard
O	1207	1212	ratio
O	1212	1213	,
O	1214	1215	1
O	1215	1216	.
O	1216	1218	18
O	1218	1219	;
O	1220	1222	95
O	1222	1223	%
O	1224	1226	CI
O	1226	1227	,
O	1228	1229	0
O	1229	1230	.
O	1230	1232	98
O	1233	1235	to
O	1236	1237	1
O	1237	1238	.
O	1238	1240	44
O	1240	1241	;
O	1242	1243	P
O	1244	1245	=
O	1245	1246	.
O	1246	1249	088
O	1249	1250	)
O	1250	1251	.

O	1252	1254	In
O	1255	1256	a
O	1257	1270	prospectively
O	1271	1278	planned
O	1279	1285	subset
O	1286	1294	analysis
O	1295	1297	of
O	1298	1306	patients
O	1307	1311	with
O	1312	1317	known
O	1318	1320	ER
O	1320	1321	+
O	1322	1325	and
O	1325	1326	/
O	1326	1328	or
O	1329	1332	PgR
O	1332	1333	+
O	1334	1340	tumors
O	1341	1342	(
O	1343	1356	approximately
O	1357	1359	78
O	1359	1360	%
O	1360	1361	)
O	1361	1362	,
B-outcome	1363	1369	median
I-outcome	1370	1373	TTP
O	1374	1377	was
B-iv-cont-median	1378	1379	8
I-iv-cont-median	1379	1380	.
I-iv-cont-median	1380	1381	2
I-iv-cont-median	1382	1388	months
O	1389	1392	for
O	1393	1404	fulvestrant
O	1405	1408	and
B-cv-cont-median	1409	1410	8
I-cv-cont-median	1410	1411	.
I-cv-cont-median	1411	1412	3
I-cv-cont-median	1413	1419	months
O	1420	1423	for
O	1424	1433	tamoxifen
O	1434	1435	(
O	1435	1441	hazard
O	1442	1447	ratio
O	1447	1448	,
O	1449	1450	1
O	1450	1451	.
O	1451	1453	10
O	1453	1454	;
O	1455	1457	95
O	1457	1458	%
O	1459	1461	CI
O	1461	1462	,
O	1463	1464	0
O	1464	1465	.
O	1465	1467	89
O	1468	1470	to
O	1471	1472	1
O	1472	1473	.
O	1473	1475	36
O	1475	1476	;
O	1477	1478	P
O	1479	1480	=
O	1480	1481	.
O	1481	1483	39
O	1483	1484	)
O	1484	1485	.

O	1486	1489	The
B-outcome	1490	1499	objective
I-outcome	1500	1508	response
I-outcome	1509	1513	rate
O	1514	1517	for
O	1518	1521	the
O	1522	1529	overall
O	1530	1540	population
O	1541	1544	was
B-iv-bin-percent	1545	1547	31
I-iv-bin-percent	1547	1548	.
I-iv-bin-percent	1548	1549	6
I-iv-bin-percent	1549	1550	%
O	1551	1555	with
O	1556	1567	fulvestrant
O	1568	1571	and
B-cv-bin-percent	1572	1574	33
I-cv-bin-percent	1574	1575	.
I-cv-bin-percent	1575	1576	9
I-cv-bin-percent	1576	1577	%
O	1578	1582	with
O	1583	1592	tamoxifen
O	1592	1593	,
O	1594	1597	and
B-iv-bin-percent	1598	1600	33
I-iv-bin-percent	1600	1601	.
I-iv-bin-percent	1601	1602	2
I-iv-bin-percent	1602	1603	%
O	1604	1607	and
B-cv-bin-percent	1608	1610	31
I-cv-bin-percent	1610	1611	.
I-cv-bin-percent	1611	1612	1
I-cv-bin-percent	1612	1613	%
O	1613	1614	,
O	1615	1627	respectively
O	1627	1628	,
O	1629	1631	in
O	1632	1635	the
O	1636	1641	known
O	1642	1649	hormone
O	1650	1658	receptor
O	1658	1659	-
O	1659	1667	positive
O	1668	1676	subgroup
O	1676	1677	.

O	1678	1682	Both
O	1683	1693	treatments
O	1694	1698	were
B-outcome	1699	1703	well
I-outcome	1704	1713	tolerated
O	1713	1714	.

O	1715	1717	In
O	1718	1721	the
O	1722	1729	overall
O	1730	1740	population
O	1740	1741	,
O	1742	1749	between
O	1749	1750	-
O	1750	1755	group
O	1756	1767	differences
O	1768	1770	in
O	1771	1779	efficacy
O	1780	1783	end
O	1784	1790	points
O	1791	1798	favored
O	1799	1808	tamoxifen
O	1808	1809	,
O	1810	1813	and
O	1814	1825	statistical
O	1826	1840	noninferiority
O	1841	1843	of
O	1844	1855	fulvestrant
O	1856	1861	could
O	1862	1865	not
O	1866	1868	be
O	1869	1881	demonstrated
O	1881	1882	.

O	1883	1890	However
O	1890	1891	,
O	1892	1894	in
O	1895	1903	patients
O	1904	1908	with
O	1909	1916	hormone
O	1917	1925	receptor
O	1925	1926	-
O	1926	1934	positive
O	1935	1941	tumors
O	1941	1942	,
O	1943	1954	fulvestrant
O	1955	1958	had
O	1959	1966	similar
O	1967	1975	efficacy
O	1976	1978	to
O	1979	1988	tamoxifen
O	1989	1992	and
O	1993	1996	was
O	1997	2001	well
O	2002	2011	tolerated
O	2011	2012	.
